The Wuhan Economic & Technological Development Zone's official account has announced that the "Longdianjing Puncture Surgery Navigation Device," developed independently by Wuhan Longdianjing Intelligent Technology Co., Ltd. — a firm headquartered in the Wuhan Economic & Technological Development Zone — has successfully obtained Class III medical device approval from the National Medical Products Administration and is now cleared for market entry. As confirmed by a representative from Wuhan Longdianjing, the device's core unit incorporates deep learning software functionalities, a fact verified by the National Medical Products Administration. This achievement signifies the official approval and market introduction of China's pioneering AI-powered percutaneous puncture navigation robot, marking a significant advancement in domestic AI technology's transition from diagnostic support to therapeutic intervention in clinical environments.